NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Biologics for rheumatoid arthritis1
Institute for Quality and Efficiency in Health Care (IQWiG).
Contents
Publishing details
Publisher
Institute for Quality and Efficiency in Health Care
Topic
Biologics for rheumatoid arthritis
Commissioning agency
Federal Joint Committee
Commission awarded on
24 November 2016
Internal Commission No.
A16-70
Address of publisher
This report was prepared in collaboration with external experts.
The responsibility for the contents of the report lies solely with IQWiG.
According to § 139b (3) No. 2 of Social Code Book (SGB) V, Statutory Health Insurance, external experts who are involved in the Institute’s research commissions must disclose “all connections to interest groups and contract organizations, particularly in the pharmaceutical and medical devices industries, including details on the type and amount of any remuneration received”. The Institute received the completed Form for disclosure of potential conflicts of interest from each external expert. The information provided was reviewed by a Committee of the Institute specifically established to assess conflicts of interests. The information on conflicts of interest provided by the external experts and external reviewers is presented in Chapter A20 of the full report. No conflicts of interest were detected that could endanger professional independence with regard to the work on the present commission.
External experts
- Dietmar Krause, Department of Medical Informatics, Biometry and Epidemiology, Ruhr-University Bochum / Group Practice for Internal Medicine and Rheumatology Gladbeck, Germany
- Bernd Richter, Cochrane Metabolic and Endocrine Disorders Group at the Institute of General Practice, University Hospital Düsseldorf, Germany
External review of the preliminary report
- Jacqueline Detert, Practice for Rheumatology and Immunology, Templin, Germany
IQWiG thanks the external experts for their collaboration in the project.
IQWiG employees
- Kirsten Janke
- Katharina Biester
- Elke Hausner
- Katharina Hirsch
- Helmut Hörn
- Michaela Florina Kerekes
- Corinna Kiefer
- Petra Kohlepp
- Christoph Schürmann
- Beate Wieseler
- 1
Translation of Chapters 1 to 6 of the final report A16-70 Biotechnologisch hergestellte Wirkstoffe bei rheumatoider Arthritis (Version 1.0; Status: 23 July 2019 [German original], 16 September 2019 [English translation]). Please note: This document is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.
- NLM CatalogRelated NLM Catalog Entries
- Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.[Arthritis Rheumatol. 2016]Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, et al. Arthritis Rheumatol. 2016 Jan; 68(1):56-66.
- A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.[Adv Ther. 2016]A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS. Adv Ther. 2016 Apr; 33(4):626-42. Epub 2016 Mar 12.
- Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.[Health Technol Assess. 2016]Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, et al. Health Technol Assess. 2016 Nov; 20(35):611-614.
- Review Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.[Health Technol Assess. 2016]Review Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, et al. Health Technol Assess. 2016 Apr; 20(35):1-610.
- Review Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.[Semin Arthritis Rheum. 2017]Review Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.Tarp S, Furst DE, Dossing A, Østergaard M, Lorenzen T, Hansen MS, Singh JA, Choy EH, Boers M, Suarez-Almazor ME, et al. Semin Arthritis Rheum. 2017 Jun; 46(6):699-708. Epub 2016 Sep 14.
- Biologics for rheumatoid arthritisBiologics for rheumatoid arthritis
- ZNF668 [Emydura macquarii macquarii]ZNF668 [Emydura macquarii macquarii]Gene ID:137144766Gene
- ZNF668 zinc finger protein 668 [Canis lupus familiaris]ZNF668 zinc finger protein 668 [Canis lupus familiaris]Gene ID:489920Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...